Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$20.13
-1.3%
$23.37
$12.21
$40.70
$571.14M-0.2456,832 shs503,622 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$15.27
+0.6%
$13.79
$5.49
$33.00
$568.50M-0.35148,808 shs109,577 shs
Savara Inc. stock logo
SVRA
Savara
$3.27
-0.6%
$2.57
$1.89
$4.70
$568.63M0.41.39 million shs843,556 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.32%-1.13%-23.23%-10.33%-45.25%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
+0.59%+3.25%+11.22%+38.32%+1,526,999,900.00%
Savara Inc. stock logo
SVRA
Savara
-0.61%+7.21%+24.81%+42.79%-22.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
1.9233 of 5 stars
3.40.00.00.02.32.50.6
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.5019 of 5 stars
3.60.00.00.01.82.50.6
Savara Inc. stock logo
SVRA
Savara
2.4461 of 5 stars
3.40.00.00.03.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$46.13129.14% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
3.20
Buy$40.38164.41% Upside
Savara Inc. stock logo
SVRA
Savara
2.83
Moderate Buy$6.1788.58% Upside

Current Analyst Ratings Breakdown

Latest PTNT, ORKA, ANAB, and SVRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
8/15/2025
Savara Inc. stock logo
SVRA
Savara
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.00
8/15/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$2.00 ➝ $5.00
8/12/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$18.00 ➝ $20.00
8/12/2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
8/7/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $45.00
7/24/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$42.00 ➝ $80.00
7/23/2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
7/21/2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M6.17N/AN/A($1.60) per share-12.58
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.10 per shareN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)

Latest PTNT, ORKA, ANAB, and SVRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.14-$0.02-$0.14N/AN/A
8/11/2025Q1 2025
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.48-$0.46+$0.02-$0.46N/AN/A
8/6/2025Q2 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.22
8.22
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
27.42
27.42
Savara Inc. stock logo
SVRA
Savara
0.25
11.08
11.08

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
24.69%
Savara Inc. stock logo
SVRA
Savara
5.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10028.00 million18.62 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A37.45 million28.20 millionN/A
Savara Inc. stock logo
SVRA
Savara
20172.84 million163.63 millionOptionable

Recent News About These Companies

Savara (NASDAQ:SVRA) Upgraded at HC Wainwright
HC Wainwright & Co. Upgrades Savara (SVRA)
Savara Inc. (SVRA) Stock Price Today - WSJ

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$20.13 -0.27 (-1.32%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$20.12 -0.01 (-0.05%)
As of 08/28/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$15.27 +0.09 (+0.59%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$15.27 0.00 (0.00%)
As of 08/28/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Savara stock logo

Savara NASDAQ:SVRA

$3.27 -0.02 (-0.61%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$3.25 -0.02 (-0.64%)
As of 08/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.